Q-omics provides the consensus-scored TTC12 profile across patient tissues and cancer cell-line models. TTC12 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in READ. Among the 18 cancer types available for tumor–normal comparison, TTC12 is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, TTC12 RNA expression shows 18,813 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight READ, KICH, and UVM as cancer lineages where TTC12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TTC12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TTC12 survival associations across molecular data types. TTC12 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (9) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TTC12 RNA expression–survival associations across cancer types. High TTC12 expression shows unfavorable associations in LGG and LIHC, but favorable associations in READ, SKCM, KIRP and UCEC. The READ Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify READ as the clearest survival context for TTC12 RNA expression.
This table summarizes TTC12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 3. The strongest signals are observed in KICH for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for TTC12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TTC12 shows lower tumor expression in KICH, THCA and BLCA and higher tumor expression in COAD, LIHC and CHOL. The KICH box plot shows higher TTC12 RNA expression in normal versus tumor tissue (log2 FC = −1.195, t-test p < 0.001).
This table shows molecular features associated with TTC12 in patient tissues and cancer cell lines. In patient samples, TTC12 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TTC12 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BONE.
